Prevention and management of carbapenem-resistant Enterobacteriaceae in haematopoietic cell transplantation. (October 2021)

• Record Type: Journal Article
• Authors: Sahitya, Dangudubiyyam Sri Krishna; Jandiyal, Aditya; Jain, Arihant; Senapati, Jayastu; Nanda, Saumya; Aggarwal, Mukul; Kumar, Pradeep; Mohapatra, Sarita; Ray, Pallab; Malhotra, Pankaj; Mahapatra, Manoranjan; Dhawan, Rishi
• Is Part Of: Therapeutic advances in infectious disease. Volume 8(2021)
• Publication Date: 2021-10
• Subjects: arbapenem-resistant enterobacteriaceae -- hematopoietic cell transplantation -- febrile neutropenia -- gut microbiome -- fecal microbiota transplantation; Communicable diseases -- Treatment -- Periodicals; Infection -- Treatment -- Periodicals; 616.905
• DOI: 10.1177/20499361211053480
• Languages: English
• ISSNs: 2049-9361

Abstract

Carbapenem-resistant Enterobacteriaceae (CRE) infections are associated with high morbidity and mortality rates in haematopoietic cell transplantation (HCT) recipients. Factors like mucositis, neutropenia, prolonged hospital stay, and frequent use of prophylactic antimicrobials make HCT recipients especially susceptible to CRE infections. Low culture positivity rates, delay in microbiological diagnosis, and resistance to empirical antimicrobial therapy for febrile neutropenia are responsible for high mortality rates in HCT recipients infected with CRE. In this review we discuss the epidemiology, diagnosis, and management of CRE infections with particular emphasis on patients undergoing HCT. We emphasise the need for preventive strategies like multidisciplinary antimicrobial stewardship, and pre-emptive screening for CRE colonisation in prospective HCT patients as measures to mitigate the adverse impact of CRE on HCT outcomes. Newer diagnostic tests like polymerase chain reaction and matrix-assisted laser desorption ionisation-time of flight (MALDI-TOF) assay that enable earlier and better identification of CRE isolates are discussed. Antimicrobial agents available against CRE, including newer agents like ceftazidime-avibactam and meropenem-vaborbactam, have been reviewed. We also discuss the data on promising experimental treatments against CRE: phage therapy and healthy donor faecal microbiota transplant. Finally, this review puts forth recommendations as per existing literature on diagnosis and management of CRE infections in blood and marrow transplant (BMT) unit.